Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
In the wake of unprecedented federal research cuts, the new $1 million emergency funding commitment aims to protect vital projects and the future of patient care.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
Clark Kent, Hannah Montana, Dexter Morgan, David Bowie and your friendly neighborhood rheumatologist: What do all of these people have in common? Chances are, they live secret lives we rarely get to peer into. Unlike Superman, Miley Stewart, Dexter Morgan and Ziggy Stardust, rheumatologists are very much real, flesh-and-blood characters. Rheumatologists also have secret lives…
Katherine Terracina, MD, & Prajakta P. Masurkar, PhD |
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.